1q6n › Citations

The structural basis for the selectivity of benzotriazole inhibitors of PTP1B.

Scapin G, Patel SB, Becker JW, Wang Q, Desponts C, Waddleton D, Skorey K, Cromlish W, Bayly C, Therien M, Gauthier JY, Li CS, Lau CK, Ramachandran C, Kennedy BP, Asante-Appiah E
Biochemistry 42 11451-9 (2003)
Related entries: 1q6j, 1q6m, 1q6p, 1q6s, 1q6t

Cited: 53 times
EuropePMC logo PMID: 14516196

Abstract

Protein tyrosine phosphatase 1B (PTP1B) has been implicated in the regulation of the insulin signaling pathway and represents an attractive target for the design of inhibitors in the treatment of type 2 diabetes and obesity. Inspection of the structure of PTP1B indicates that potent PTP1B inhibitors may be obtained by targeting a secondary aryl phosphate-binding site as well as the catalytic site. We report here the crystal structures of PTP1B in complex with first and second generation aryldifluoromethyl-phosphonic acid inhibitors. While all compounds bind in a previously unexploited binding pocket near the primary binding site, the second generation compounds also reach into the secondary binding site, and exhibit moderate selectivity for PTP1B over the closely related T-cell phosphatase. The molecular basis for the selectivity has been confirmed by single point mutation at position 52, where the two phosphatases differ by a phenylalanine-to-tyrosine switch. These compounds present a novel platform for the development of potent and selective PTP1B inhibitors.

Articles - 1q6n mentioned but not cited (4)

  1. Reverse pharmacophore mapping and molecular docking studies for discovery of GTPase HRas as promising drug target for bis-pyrimidine derivatives. Kumar S, Singh J, Narasimhan B, Shah SAA, Lim SM, Ramasamy K, Mani V. Chem Cent J 12 106 (2018)
  2. Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design. Vidović D, Schürer SC. J Med Chem 52 6649-6659 (2009)
  3. Antihypertensive effect and mechanism of the traditional recipe of medicine food homology (Buyang Huanwu Decoction) in China: Meta analysis and network pharmacological exploration. Li B, Lu C, Liu Y, Wang X, Fu H, Li C, Sun M, Zhang Y, Li M. Heliyon 10 e23474 (2024)
  4. research-article Native dynamics and allosteric responses in PTP1B probed by high-resolution HDX-MS. Woods VA, Abzalimov RR, Keedy DA. bioRxiv 2023.07.12.548582 (2023)


Reviews citing this publication (7)

  1. Recent advances in protein tyrosine phosphatase 1B inhibitors. Taylor SD, Hill B. Expert Opin Investig Drugs 13 199-214 (2004)
  2. Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer. Bollu LR, Mazumdar A, Savage MI, Brown PH. Clin Cancer Res 23 2136-2142 (2017)
  3. Benzotriazole: An overview on its versatile biological behavior. Briguglio I, Piras S, Corona P, Gavini E, Nieddu M, Boatto G, Carta A. Eur J Med Chem 97 612-648 (2015)
  4. Bidentate inhibitors of protein tyrosine phosphatases. Low JL, Chai CL, Yao SQ. Antioxid Redox Signal 20 2225-2250 (2014)
  5. PTP1b Inhibition, A Promising Approach for the Treatment of Diabetes Type II. Eleftheriou P, Geronikaki A, Petrou A. Curr Top Med Chem 19 246-263 (2019)
  6. The development of protein tyrosine phosphatase1B inhibitors defined by binding sites in crystalline complexes. Zhang Y, Du Y. Future Med Chem 10 2345-2367 (2018)
  7. Can Allostery Be a Key Strategy for Targeting PTP1B in Drug Discovery? A Lesson from Trodusquemine. Maccari R, Ottanà R. Int J Mol Sci 24 9621 (2023)

Articles citing this publication (42)

  1. Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. Abad-Zapatero C, Perišić O, Wass J, Bento AP, Overington J, Al-Lazikani B, Johnson ME. Drug Discov Today 15 804-811 (2010)
  2. New Frontiers in Druggability. Kozakov D, Hall DR, Napoleon RL, Yueh C, Whitty A, Vajda S. J Med Chem 58 9063-9088 (2015)
  3. 5-Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases. Maccari R, Paoli P, Ottanà R, Jacomelli M, Ciurleo R, Manao G, Steindl T, Langer T, Vigorita MG, Camici G. Bioorg Med Chem 15 5137-5149 (2007)
  4. Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening. Taha MO, Bustanji Y, Al-Bakri AG, Yousef AM, Zalloum WA, Al-Masri IM, Atallah N. J Mol Graph Model 25 870-884 (2007)
  5. Unlocking the N(2)  selectivity of benzotriazoles: regiodivergent and highly selective coupling of benzotriazoles with allenes. Xu K, Thieme N, Breit B. Angew Chem Int Ed Engl 53 7268-7271 (2014)
  6. 5-Arylidene-2-phenylimino-4-thiazolidinones as PTP1B and LMW-PTP inhibitors. Ottanà R, Maccari R, Ciurleo R, Paoli P, Jacomelli M, Manao G, Camici G, Laggner C, Langer T. Bioorg Med Chem 17 1928-1937 (2009)
  7. Cellular inhibition of protein tyrosine phosphatase 1B by uncharged thioxothiazolidinone derivatives. Stuible M, Zhao L, Aubry I, Schmidt-Arras D, Böhmer FD, Li CJ, Tremblay ML. Chembiochem 8 179-186 (2007)
  8. Identification of novel PTP1B inhibitors by pharmacophore based virtual screening, scaffold hopping and docking. Balaramnavar VM, Srivastava R, Rahuja N, Gupta S, Rawat AK, Varshney S, Chandasana H, Chhonker YS, Doharey PK, Kumar S, Gautam S, Srivastava SP, Bhatta RS, Saxena JK, Gaikwad AN, Srivastava AK, Saxena AK. Eur J Med Chem 87 578-594 (2014)
  9. Structure of Leishmania mexicana phosphomannomutase highlights similarities with human isoforms. Kedzierski L, Malby RL, Smith BJ, Perugini MA, Hodder AN, Ilg T, Colman PM, Handman E. J Mol Biol 363 215-227 (2006)
  10. Synthesis, biological activity and structure-activity relationships of new benzoic acid-based protein tyrosine phosphatase inhibitors endowed with insulinomimetic effects in mouse C2C12 skeletal muscle cells. Ottanà R, Maccari R, Mortier J, Caselli A, Amuso S, Camici G, Rotondo A, Wolber G, Paoli P. Eur J Med Chem 71 112-127 (2014)
  11. Identification of ligand binding sites of proteins using the Gaussian Network Model. Tuzmen C, Erman B. PLoS One 6 e16474 (2011)
  12. Structure-based optimization of benzoic acids as inhibitors of protein tyrosine phosphatase 1B and low molecular weight protein tyrosine phosphatase. Maccari R, Ottanà R, Ciurleo R, Paoli P, Manao G, Camici G, Laggner C, Langer T. ChemMedChem 4 957-962 (2009)
  13. Druggability analysis and classification of protein tyrosine phosphatase active sites. Ghattas MA, Raslan N, Sadeq A, Al Sorkhy M, Atatreh N. Drug Des Devel Ther 10 3197-3209 (2016)
  14. Arenediazonium tetrafluoroborates in palladium-catalyzed C-P bond-forming reactions. Synthesis of arylphosphonates, -phosphine oxides, and -phosphines. Berrino R, Cacchi S, Fabrizi G, Goggiamani A, Stabile P. Org Biomol Chem 8 4518-4520 (2010)
  15. PTP1B-dependent insulin receptor phosphorylation/residency in the endocytic recycling compartment of CHO-IR cells. Cromlish WA, Tang M, Kyskan R, Tran L, Kennedy BP. Biochem Pharmacol 72 1279-1292 (2006)
  16. Fullerene derivatives as a new class of inhibitors of protein tyrosine phosphatases. Kobzar OL, Trush VV, Tanchuk VY, Zhilenkov AV, Troshin PA, Vovk AI. Bioorg Med Chem Lett 24 3175-3179 (2014)
  17. Prediction of enzyme inhibition and mode of inhibitory action based on calculation of distances between hydrogen bond donor/acceptor groups of the molecule and docking analysis: An application on the discovery of novel effective PTP1B inhibitors. Eleftheriou P, Petrou A, Geronikaki A, Liaras K, Dirnali S, Anna M. SAR QSAR Environ Res 26 557-576 (2015)
  18. An RNA aptamer that selectively inhibits the enzymatic activity of protein tyrosine phosphatase 1B in vitro. Townshend B, Aubry I, Marcellus RC, Gehring K, Tremblay ML. Chembiochem 11 1583-1593 (2010)
  19. Discovery of orally active, potent, and selective benzotriazole-based PTP1B inhibitors. Patel D, Jain M, Shah SR, Bahekar R, Jadav P, Darji B, Siriki Y, Bandyopadhyay D, Joharapurkar A, Kshirsagar S, Patel H, Shaikh M, Sairam KV, Patel P. ChemMedChem 6 1011-1016 (2011)
  20. Design and synthesis of new potent PTP1B inhibitors with the skeleton of 2-substituted imino-3-substituted-5-heteroarylidene-1,3-thiazolidine-4-one: Part I. Meng G, Zheng M, Wang M, Tong J, Ge W, Zhang J, Zheng A, Li J, Gao L, Li J. Eur J Med Chem 122 756-769 (2016)
  21. Design and synthesis of paracaseolide A analogues as selective protein tyrosine phosphatase 1B inhibitors. Yin JP, Tang CL, Gao LX, Ma WP, Li JY, Li Y, Li J, Nan FJ. Org Biomol Chem 12 3441-3445 (2014)
  22. Discovery of 4-[(5-arylidene-4-oxothiazolidin-3-yl)methyl]benzoic acid derivatives active as novel potent allosteric inhibitors of protein tyrosine phosphatase 1B: In silico studies and in vitro evaluation as insulinomimetic and anti-inflammatory agents. Ottanà R, Paoli P, Naß A, Lori G, Cardile V, Adornato I, Rotondo A, Graziano ACE, Wolber G, Maccari R. Eur J Med Chem 127 840-858 (2017)
  23. Protein tyrosine phosphatases: Ligand interaction analysis and optimisation of virtual screening. Ghattas MA, Atatreh N, Bichenkova EV, Bryce RA. J Mol Graph Model 52 114-123 (2014)
  24. Letter Classification of binding site conformations of protein tyrosine phosphatase 1B. Tanchuk VY, Tanin VO, Vovk AI. Chem Biol Drug Des 80 121-128 (2012)
  25. In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complications-A Structure-Activity Relationship Study on Inhibitors of Aldose Reductase and Protein Tyrosine Phosphatase 1B. Ottanà R, Paoli P, Cappiello M, Nguyen TN, Adornato I, Del Corso A, Genovese M, Nesi I, Moschini R, Naß A, Wolber G, Maccari R. Molecules 26 E330 (2021)
  26. Structures of the first representatives of Pfam family PF06938 (DUF1285) reveal a new fold with repeated structural motifs and possible involvement in signal transduction. Han GW, Bakolitsa C, Miller MD, Kumar A, Carlton D, Najmanovich RJ, Abdubek P, Astakhova T, Axelrod HL, Chen C, Chiu HJ, Clayton T, Das D, Deller MC, Duan L, Ernst D, Feuerhelm J, Grant JC, Grzechnik A, Jaroszewski L, Jin KK, Johnson HA, Klock HE, Knuth MW, Kozbial P, Krishna SS, Marciano D, McMullan D, Morse AT, Nigoghossian E, Okach L, Reyes R, Rife CL, Sefcovic N, Tien HJ, Trame CB, van den Bedem H, Weekes D, Xu Q, Hodgson KO, Wooley J, Elsliger MA, Deacon AM, Godzik A, Lesley SA, Wilson IA. Acta Crystallogr Sect F Struct Biol Cryst Commun 66 1218-1225 (2010)
  27. (-)- and (+)-Securidanes A and B, Natural Triarylmethane Enantiomers: Structure and Bioinspired Total Synthesis. Zhou B, Liu DX, Yuan XJ, Li JY, Xu YC, Li J, Li Y, Yue JM. Research (Wash D C) 2018 2674182 (2018)
  28. Rhodium-Catalyzed Regioselective N2 -Alkylation of Benzotriazoles with Diazo Compounds/Enynones via a Nonclassical Pathway. Wang K, Chen P, Ji D, Zhang X, Xu G, Sun J. Angew Chem Int Ed Engl 57 12489-12493 (2018)
  29. Copper-catalyzed cascade cyclization reaction of 2-haloaryltriazenes and sodium azide: selective synthesis of 2H-benzotriazoles in water. Shang X, Zhao S, Chen W, Chen C, Qiu H. Chemistry 20 1825-1828 (2014)
  30. Dual Targeting of PTP1B and Aldose Reductase with Marine Drug Phosphoeleganin: A Promising Strategy for Treatment of Type 2 Diabetes. Genovese M, Imperatore C, Casertano M, Aiello A, Balestri F, Piazza L, Menna M, Del Corso A, Paoli P. Mar Drugs 19 535 (2021)
  31. Pharmacophore modeling for protein tyrosine phosphatase 1B inhibitors. Bharatham K, Bharatham N, Lee KW. Arch Pharm Res 30 533-542 (2007)
  32. Analysis of structural water and CH···π interactions in HIV-1 protease and PTP1B complexes using a hydrogen bond prediction tool, HBPredicT. Yesudas JP, Sayyed FB, Suresh CH. J Mol Model 17 401-413 (2011)
  33. Design and synthesis of imidazolidine-2,4-dione derivatives as selective inhibitors by targeting protein tyrosine phosphatase-1B over T-cell protein tyrosine phosphatase. Ma Y, Sun SX, Cheng XC, Wang SQ, Dong WL, Wang RL, Xu WR. Chem Biol Drug Des 82 595-602 (2013)
  34. Design, synthesis, biological activity and molecular dynamics studies of specific protein tyrosine phosphatase 1B inhibitors over SHP-2. Sun SX, Li XB, Liu WB, Ma Y, Wang RL, Cheng XC, Wang SQ, Liu W. Int J Mol Sci 14 12661-12674 (2013)
  35. Enzyme occupancy measurement of intracellular protein tyrosine phosphatase 1B using photoaffinity probes. Skorey K, Waddleton D, Therien M, Leriche T. Anal Biochem 349 49-61 (2006)
  36. Facile synthesis of novel benzotriazole derivatives and their antibacterial activities. Wan J, Lv PC, Tian NN, Zhu HL. J Chem Sci (Bangalore) 122 597-606 (2010)
  37. Nitrate in the active site of protein tyrosine phosphatase 1B is a putative mimetic of the transition state. Kenny PW, Newman J, Peat TS. Acta Crystallogr D Biol Crystallogr 70 565-571 (2014)
  38. Combined Ligand- and Receptor-Based Virtual Screening Methodology to Identify Structurally Diverse Protein Tyrosine Phosphatase 1B Inhibitors. Gimeno A, Ardid-Ruiz A, Ojeda-Montes MJ, Tomás-Hernández S, Cereto-Massagué A, Beltrán-Debón R, Mulero M, Valls C, Aragonès G, Suárez M, Pujadas G, Garcia-Vallvé S. ChemMedChem 13 1939-1948 (2018)
  39. Molecular Dynamics Simulations of A27S and K120A Mutated PTP1B Reveals Selective Binding of the Bidentate Inhibitor. Chen X, Liu X, Gan Q, Feng C, Zhang Q. Biomed Res Int 2019 9852897 (2019)
  40. Surface-enhanced Raman scattering and DFT computational studies of a benzotriazole derivative. Li MY, Liao Q, Zhang M, Ai XC, Li FY. J Mol Struct 888 2-6 (2008)
  41. Molecular and Biological Investigation of Isolated Marine Fungal Metabolites as Anticancer Agents: A Multi-Target Approach. Bogari HA, Elhady SS, Darwish KM, Refaey MS, Mohamed RA, Abdelhameed RFA, Almalki AJ, Aldurdunji MM, Lashkar MO, Alshehri SO, Malatani RT, Yamada K, Khedr AIM. Metabolites 13 162 (2023)
  42. Unified access to up-to-date residue-level annotations from UniProtKB and other biological databases for PDB data. Choudhary P, Anyango S, Berrisford J, Tolchard J, Varadi M, Velankar S. Sci Data 10 204 (2023)


Quick links